SOVREMENNAYA PEDIATRIYA.2019.3(99):18-24; doi 10.15574/SP.2019.99.18

Raus I. V.
Kyiv City Hospital No.5, Ukraine
Kyiv City AIDS Center, Ukraine

Children living with HIV are at increased risk of disease from bacterial infections as Haemophilus influenzae type b (Hib) and pertussis. Data are limited on immunity to these vaccine-peventable diseases in HIV-infected children.

Objective: to evaluate immunity to Hib and pertussis in children with perinatal HIV-infection.

Materials and Methods. We conducted a retrospective single-center cohort study of HIV-infected children and analyzed their vaccine coverage against pertussis and Hib. We evaluated the level of IgG antibodies against capsular polyribosylribitol phosphate (PRP) of Hib and pertussis toxin in HIV-infected adolescents (n=51). The comparison group included 22 healthy children, not infected with HIV, of the same age.

Results: Immunization coverage of HIV-infected children was 63.6% for pertussis and 16.8% for Hib. Most HIV-infected children (43/51, 84.3%) had antibodies to Hib≥1 μg/ml, which is considered to be protective against invasive forms of as H. influenzae type b disease. High levels of antibodies to pertussis toxin (>100 IU /ml) was detected in 32/51 (62.7%) children, living with HIV.

Conclusion. It is important to hold vaccination against Hib in pre-school age children with HIV who have not received a vaccine before, or have not been fully vaccinated. The presence of high levels of antibodies to pertussis toxin in most children with HIV infection indicates a high incidence of pertussis in school age. In order to protect HIV-infected children against pertussis, it is advisable to recommend the administration of booster dose of the acellular vaccine against pertussis in children of school age.

Key words: HIV-infection, children, Haemophilus influenza type b, pertussis, immunity.

REFERENCES

1. Volokha AP, Chernyshova LI, Raus IV. (2013). Problemy imunizatsiyi VIL-infikovanykh ditey. Sovremennaya pediatriya. 2(50): 10–17.

2. Volokha A, Chernyshova L, Raus I. (2015). Vaktsynacia ditey z VIL-infektsieiu. Metodychni rekomendatsii: 28.

3. Raus IV, Volokha АP, Chernyshova LI. (2018). Postvaccinal immunity in children living with HIV infection. Sovremennaya pediatriya. 6(94): 41–46. https://doi.org/10.15574/SP.2018.94.41

4. Pro poriadok provedennia profilaktychnykh shcheplen v Ukraini ta kontrol yakosti y obihu medychnykh imunobiolohichnykh preparativ. Nakaz MOZ Ukrainy vid 16.09.2011 No.595 (2011). http://www.moz.gov.ua.

5. Chernyshova LI, Lapii FI, Volokha A.P (redaktory) (2018). Imunoprofilaktyka infektsiinykh khvorob. Kyiv: VSV Medytsyna.

6. Abzug MJ, Song Lin-Ye, Fenton T et al. (2007). Pertussis boster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics. 120 (5): 1190—1202. https://doi.org/10.1542/peds.2007-0729; PMid:17938165

7. Anukam KC, Osazuwa EE, Mbata TI, Ahonkhai IN. (2004). Increased incidence of pertussis and parapertussis in HIV-1 positive adolescents vaccinated previously wіth whole-cell vaccine. World Journal of Microbiology and Biotechnology. 20: 231—234. https://doi.org/10.1023/B:WIBI.0000023825.36332.f1

8. Arvas A, Gur E, Hrisi Bahar H et al. (2008). Haemophilus influenzae type b antibodies in vaccinated and non-vaccinated children. Pediatrics International. 50: 469—473. https://doi.org/10.1111/j.1442-200X.2008.02591.x; PMid:19143969

9. Arya BK, Bhattacharya SD, Sutcliffe CG et al. (2016). Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenza type b conjugate vaccine in Indian children living with HIV. Vaccine. https://doi.org/10.1016/j.vaccine.2016.03.012; PMid:26988256

10. Bamford A, Emma C, Manno EC et al. (2016). Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonization. Vaccine. 34: 5587—5594. https://doi.org/10.1016/j.vaccine.2016.09.035; PMid:27727030

11. Briere EC, Rubin L, Moro PL. (2014). Prevention and Control of Haemophilus influenzaetype b disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 63

12. Cagigi A, Cotugno N, Giaquinto C et al. (2012). Immune reconstitution and vaccination outcome in HIV-infected children. Human Vaccine and Immunotherapeutics. 8: 12: 1784—1794. https://doi.org/10.4161/hv.21827; PMid:22906931 PMCid:PMC3656066

13. Cordero E, Pachon J, Rivero A. et al. (2000). Haemophilus influenzae-рneumonia in Human Immunodeficiency Virus-Infected рatients. Clinical Infectious Diseases. 30: 461—5. https://doi.org/10.1086/313690; PMid:10722428

14. Kerneis S, Launay O, Turbelin C et al. (2014). Long-term immune responses to vaccination in HIV-Infected patients: a systematic review and meta-analysis. Clinical Infectious Diseases. 58(8): 1130—9. https://doi.org/10.1093/cid/cit937; PMid:24415637 PMCid:PMC4761378

15. Madhi SA, Kuwanda L, Saarinen L et al. (2005, Dec). Immunogenicity and effectiveness of Haemophilus influenza type b conjugate vaccine in HIV infected and uninfected African children. Vaccine. 23(48—49): 5517—5525. https://doi.org/10.1016/j.vaccine.2005.07.038; PMid:16107294

16. Mangtani P, Mulholland K, Madhi SA et al. (2010). Heamophilus influenza type B disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccine. Vaccine. 28: 1677—1683. https://doi.org/10.1016/j.vaccine.2009.12.011; PMid:20034606

17. Manno EC, Bamford A, Rojo P, Volokha A et al. (2015, 19—22 July). Immunization practice and vaccine safety perception in centres caring for children with perinatally acquired HIV: results from the Pediatric European Network for Treatment of AIDS survey. Abstract book of 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention: 272.

18. Melvin AJ. (2003). Response to immunization with measles, tetanus, and Haemophilus influenza type b vaccines in children who have Human Immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics. 111: 641—644. https://doi.org/10.1542/peds.111.6.e641; PMid:12777579

19. Menson EN, Mellado MJ, Bamford A et al. (2012). Guidance on vaccination of HIV-Infected children in Europe. HIV Medicine. 13(6): 333—336. https://doi.org/10.1111/j.1468-1293.2011.00982.x; PMid:22296225

20. Moss WJ, Sutcliff CG. (2010). Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis. 10: 630—4. https://doi.org/10.1016/S1473-3099(10)70116-X

21. Nix EВ, Hawdon N, Gravelle S et al. (2012). Risk of invasive Haemophilus influenzae Type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clinical and Vaccine Immunology. 19(5): 766—771. https://doi.org/10.1128/CVI.05675-11; PMid:22398246 PMCid:PMC3346318

22. Obaro SK, Pugatch D, Luzuriaga K. (2004). Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis. 4: 510—518. https://doi.org/10.1016/S1473-3099(04)01106-5

23. Perrett КР, John ТМ, Jin С et al. (2014). Long-term persistence of immunity and B-cell memory following Haemophilus influenzaetype b conjugate vaccination in early childhood and response to booster. Clinical Infectious Diseases. 58(7): 949—59. https://doi.org/10.1093/cid/ciu001; PMid:24403544

24. Read JS et al. (1998). The immunogenicity of Haemophilus influenzae Type b conjugate vaccines in children born with Human Immunodeficiency virus-infected women. Pediatr Infect Dis J. 17: 391—97. https://doi.org/10.1097/00006454-199805000-00009; PMid:9613652

25. Rubin LG., Levin M.J., Per Ljungman et al. (2014). 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clinical Infectious Diseases. 58(3): 44—100. https://doi.org/10.1093/cid/cit684; PMid:24311479

26. Sticchi L, Bruzzone B, Caligiuri P et al. (2015). Seroprevalence and vaccination coverage of vaccinepreventable diseases in perinatally HIV-1-infected patients. Human Vaccines & Immunotherapeutics. 11: 1: 263—269. https://doi.org/10.4161/hv.36162; PMid:25483544 PMCid:PMC4514310

27. Succi R, Margot R, Krauss MR, Harris R et al. (2018). Immunity after childhood vaccinations in perinatally HIV-exposed children with and without HIV infection in Latin America. The Pediatric Infectious Disease Journal. 37 (4). https://doi.org/10.1097/INF.0000000000001831; PMid:29140938 PMCid:PMC5849487

28. Tejiokem MC, Njampero E, Gouandjika J et al. (2009, Apr). Whole-cell pertussis vaccine induces low antibody levels in Human Immunodeficiency virus-infected children living in Sub-Saharan Africa. Clinical and Vaccine Immunology. 16(4): 479—483. https://doi.org/10.1128/CVI.00312-08; PMid:19193831 PMCid:PMC2668289

29. Troy SB et al. (2016). Seroprevalence of pertussis infection in HIV-infected adults in United States. J Acquir Immune Defic Syndr. 73(3): 282—286. https://doi.org/10.1097/QAI.0000000000001037; PMid:27105050 PMCid:PMC5065371

30. Ulanova M, Hawdon N, Nix E et al. (2011). Immune response of adults with secondary immunodeficiency to pediatric Haemophilus influenzae type b (Hib) vaccine. Allergy, Asthma & Clinical Immunology. 7(2): A23. https://doi.org/10.1186/1710-1492-7-S2-A23; PMCid:PMC3242185

Article received: Jan 09, 2019. Accepted for publication: Mar 27, 2019.